Northland Securities Reaffirms Corporate Rating for ImmuPharma PLC (IMM)
A number of other research analysts have also recently commented on IMM. Panmure Gordon reaffirmed a buy rating and set a GBX 100 ($1.31) price target on shares of ImmuPharma PLC in a research report on Wednesday, September 14th. Northland Capital Partners initiated coverage on ImmuPharma PLC in a research report on Wednesday, July 20th. They set a buy rating and a GBX 171 ($2.23) price target on the stock.
ImmuPharma PLC (LON:IMM) opened at 38.00 on Wednesday. ImmuPharma PLC has a 12 month low of GBX 19.10 and a 12 month high of GBX 48.88. The company’s market cap is GBX 46.28 million. The company has a 50 day moving average price of GBX 37.51 and a 200-day moving average price of GBX 32.96.
About ImmuPharma PLC
ImmuPharma plc (ImmuPharma) is a United Kingdom-based is a drug discovery and development company. Its research operations are in France. The Company is engaged in the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions, such as autoimmune diseases. ImmuPharma is engaged in developing drug candidates for five different medical conditions.
Receive News & Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.